on october , pfizer announced the official opening of china research and development center (crdc) in shanghai. pfizer global research and development’s center is mainly engaged in drug development activities. much of the facility's capacity is devoted to the study design, data management and statistical analysis of global phase i-iv clinical trials, as well as the clinical study report process. in addition, crdc is a part of pfizer global safety and risk management and covers the functions of safety data processing and assessment. the center also trains pfizer employees in china and throughout the asia region in internationally recognized good clinical practice standards.<br>輝瑞公司于2005年10月31日宣布輝瑞中國研發(fā)中心正式在上海揭幕。輝瑞中國研發(fā)中心主要為全球輝瑞藥物開發(fā)提供支持工作。大部分的功能是圍繞在i-iv期臨床試驗(yàn)研究設(shè)計(jì)、數(shù)據(jù)管理和生物統(tǒng)計(jì)分析、以及臨床試驗(yàn)報(bào)告的部分準(zhǔn)備工作。此外，該中心是輝瑞全球安全和風(fēng)險(xiǎn)管理部的一個(gè)分支，負(fù)責(zé)安全數(shù)據(jù)處理和評(píng)估工作。研發(fā)中心還將為輝瑞公司在中國及亞洲的其它運(yùn)營部門的員工提供國際標(biāo)準(zhǔn)的臨床試驗(yàn)管理規(guī)范(gcp)的技術(shù)培訓(xùn)。